Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

OAS1 and OAS3 genetic variants enhance inflammatory responses to SARS-CoV-2

  • DeDiego, Marta L.
  • López-Fernández-Sobrino, Raúl
  • Pedragosa, Jordi
  • López-García, Darío
  • Nogales, Aitor
  • Durbán, Jordi
  • Cardona, Fernando
  • Llucià-Carol, Laia
  • Rivero, Vanessa
  • Vázquez-Utrilla, Paula
  • Sanchez-Grande, Laura Palomo
  • Cobo Cano, Miriam
  • Lloret Iglesias, Lara
  • Márquez-Kisinousky, Leonardo
  • Ruíz-Jaén, Francisca
  • Rojo, Silvia
  • Fiz-López, Aida
  • Arribas, Elisa
  • Cal-Sabater, Paloma de la
  • Bernardo, David
  • Pérez-Tur, Jordi
  • COVID Human Genetic Effort
COVID Human Genetic Effort: et al., Recessive deficiency in 2′,5′-oligoadenylate synthetase (OAS) or RNase L can cause systemic inflammation in children with SARS-CoV-2 infection, but its role in adult respiratory disease is unclear. We analyzed rare OAS1/OAS3 variants and the common OAS1 rs10774671 polymorphism in 342 COVID-19 patients, assessing enzymatic activity, RNase L activation, viral replication, and inflammation in cell systems and Oas3-deficient mice. Rare heterozygous variants showed impaired RNase L activation but were not enriched in pneumonia cases. In contrast, the rs10774671 A/A genotype (OAS1-p42 isoform) was associated with severe disease (OR = 2.28; 95% CI = 1.13–4.58; p = 0.0107) and reduced viral control despite intact RNase L activation. OAS3 and OAS1-p46 isoform limited viral replication and inflammatory responses, whereas Oas3-deficient mice showed increased cytokines. These findings suggest that common OAS1 variation influences COVID-19 severity, while rare OAS variants may affect inflammation regulation rather than respiratory pathology., Supported by the Spanish National Research Council (CSIC) through the Fondo COVID-19 (Ref. CSIC-202020E086). This research work was also funded by the European Commission – NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global). Funds were also provided by the Spanish Ministry of Science and Innovation, PID2021-123810OB-I00 funded by MCIN/AEI/10.13039/50110.00110.33 and CNS2022-135276. We acknowledge the EASI-Genomics initiative (PID12396) that received funds from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 824110., Peer reviewed